OncoMatch/Clinical Trials/NCT06475300
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Is NCT06475300 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including BL-B01D1 and PD-1 Monoclonal Antibody for non-small cell lung cancer.
Treatment: BL-B01D1 · PD-1 Monoclonal Antibody — This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma and other solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Tumor Agnostic
Biomarker criteria
Excluded: ALK fusion
Excluded: EGFR sensitizing mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic chemotherapy
Stage 1 EGFR-sensitive mutant non-small cell lung cancer patients with systemic chemotherapy
Cannot have received: systemic therapy
Stage 2 patients who had received previous systemic therapy
Cannot have received: anti-tumor therapy (chemotherapy, biological therapy, mitomycin, nitrosoureas, fluorouracil class oral drugs)
Anti-tumor therapy such as chemotherapy or biological therapy has been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Fluorouracil class oral drugs, etc.
Lab requirements
Cardiac function
no serious cardiac dysfunction, left ventricular ejection fraction 50% or higher
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06475300 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic chemotherapy, systemic therapy, anti-tumor therapy disqualifies patients from enrollment.
Are patients with ALK alterations eligible?
No. ALK fusion is an exclusion criterion.
Are patients with EGFR alterations eligible?
No. EGFR sensitizing mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify